Analysis of Cord Blood Banking
The first cord blood transplant was performed in 1988. Since then, more than 8,000 transplants have occurred.Families know that there is only one opportunity – at birth – to collect these genetically unique stem cells and if not taken, the cord blood is simply discarded.This technology to collect and store newborn’s umbilical cord blood stem cells has only been widely available since late 1995.Currently, thousands of parents are taking advantage of this once-in-a-lifetime opportunity. New treatments with cord blood focus on regenerative medicine – where doctors use stem cells to repair damaged tissues and organs in the body.
In the near future, it will become a common practice to store Cord Blood as future insurance against many diseases.Families recognize that their baby’s cord blood may offer a lifetime of protection:
- The baby’s cord blood may be used to treat nearly 80 diseases. Stem cells have been used for decades in lifesaving treatments for diseases including leukemia, other cancers, and blood disorders.
- Cord blood stem cells are showing significant potential to treat conditions that have no cure today – like juvenile diabetes and brain injury.
- The baby’s cord blood is immediately available for the family if needed, and faster treatment is always better.
- For use in regenerative medicine therapies using cord blood, the child’s own stem cells are required.
- For treating cancers and blood disorders in transplant medicine, having the family’s own cord blood available may offer significant advantages if ever needed, including fewer complications, improved survival, and a better quality of life without the need for continual anti-rejection medications.
Some families have more defined risk factors, but most families bank for the security of knowing the health benefits that stem cells may someday offer their children, themselves, or other family members.
Cord Blood America has generated lots of interest in the investing community recently.
Recently Cord Blood America in Las Vegas has received lot of news coverage and is traded publically since 2003.
CBAI has signed a License and Cooperation Agreement for the processing and storage of umbilical cord blood in China with AXM Pharma, Inc.
They are actually located on Helm Drive in Las Vegas and currently hold the record for the largest cryogenic storage facility in the world. Readers must be aware of the Cryogenic technology used in rocket launchers.
The principle of cryogenic plants operation is based on the air liquefaction and its subsequent separation with the recovery of nitrogen, oxygen, and argon.
Information from A Study of Cord Blood Preservation
